CD200 and acute lymphoblastic leukemia: In pediatric B cell acute lymphoblastic leukemia (B-ALL), Aref et al. reported decreased responses to remission-induction therapy for CD200+ cases (19/28 or 67.8%) relative to CD200− cases (14/15 or 93.3%) along with significantly shorter overall survival (OS) and disease-free survival (DFS) [25].